RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsThis is being reposted for those "deniers" and "complainers" who haven't read what's been posted or the reasons why it has been posted:
What differs from Biohaven Pharmaceuticals platform technology that was acquired by Pfizer for US$11.6 Billion is that ONCY's platform technology in pleareorep addresses the high value cancer market in a number of cancers with unmet needs, whereas Biohaven's technology is to treat migraine headache, .... so with ONCY's breast cancer data now available to the sponsors of the Bracelet-1 Phase 2 clinical trial (Merck KGaA and Pfizer) these new results added in to the pancreatic results could have ONCY's M&A acquisition value north of >US$ 12 Billion.